How many clinical trials are studying Dextromethorphan?

3 recruiting trials in our tracked data involve Dextromethorphan.

What conditions is Dextromethorphan being studied for?

In our tracked recruiting trials, Dextromethorphan is being studied in trials for Active Ulcerative Colitis, Anxiety, Body Dysmorphic Disorders.

Yes. According to the FDA drug label available through openFDA, Dextromethorphan is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA-approved: Yes. Dextromethorphan appears in the FDA drug-label database. Marketed as Dextromethorphan HBr 15 mg.

Use temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold

Reason (FDA)	Classification	Status	Initiated
Labeling: Label Mix-Up; Bottles of Mucinex Fast-Max liquid are correctly labeled on the front of the label, however the back of the bottle where the Drug Facts labeling is, is missing certain Active Ingredients such as acetaminophen, phenylephrine, dextromethorphan, diphenhydramine, and/or guaifenes — Reckitt Benckiser LLC	Class I (FDA: reasonable probability of serious harm or death)	Terminated	2015-04-15
CGMP Deviations: products were manufactured with lack of process validation, cleaning validation, stability studies, and other current good manufacturing practice violations. — Pharma-Natural Inc.	Class II (FDA: may cause temporary or reversible harm)	Terminated	2019-06-21
Microbial Contamination of Non-Sterile Products — Efficient Laboratories, Inc.	Class II (FDA: may cause temporary or reversible harm)	Terminated	2021-08-24
Labeling: Incorrect Instructions; The product has been found to provide incorrect dosage information on its label due to a typographical error. The drug facts label incorrectly states children 6 to under 2 years of age, 1 teaspoonful every 4 hours, not to exceed 4 teaspoonfuls in 24 hours or directe — Novis PR, Inc.	Class I (FDA: reasonable probability of serious harm or death)	Terminated	2019-05-28
Product mix-up: incorrect product was found inside the G-Supress DX product carton. — Novis PR, LLC dba Kramer Novis	Class I (FDA: reasonable probability of serious harm or death)	Terminated	2023-04-20

Early Phase 1 1 Phase 1 1 Phase 2 1

Condition	Trials
Active Ulcerative Colitis	1
Anxiety	1
Body Dysmorphic Disorders	1
Fibromyalgia	1
Fibromyalgia, Primary	1
Illness Anxiety Disorder	1
Obsessive-Compulsive Disorder	1
Somatic Symptom Disorder	1
Ulcerative colitis	1

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 17 locations
Psilocybin-facilitated Treatment for Chronic Pain
NCT05068791 · Phase: Early Phase 1 · Ages: 25 Years to 65 Years · Sex: Female · 1 location
Study of Dextromethorphan in OCD and Related Disorders
NCT04899687 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Yes, marketed as Dextromethorphan HBr 15 mg.

3 recruiting trials across 9 conditions.

No. For the full record, search ClinicalTrials.gov.